|
Press Releases
July 17, 2008
Provectus' Lead Investigator for Phase 2 Melanoma Study to Address the Inaugural Sydney Cancer Conference 2008
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that the Lead Investigator for its Phase 2 melanoma study, Professor John F Thompson, MD, will address the inaugural Sydney Cancer Conference 2008 (SCC2008).
Read the complete article here.
July 7, 2008
First Twenty-Five Percent of Subjects in Phase 2 Melanoma Clinical Trial Treated
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in Provectus Pharmaceuticals' Phase 2 clinical trial of PV-10.
Read the complete article here.
July 1, 2008
Provectus Pharmaceuticals Announces Upcoming Investment Community Events
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that its Chairman and CEO, Craig Dees, Ph.D., will be participating in several investment community events over the next two months.
Read the complete article here.
June 13, 2008
Industry Supports International Research on New Melanoma Treatments
KNOXVILLE, Tenn. & SYDNEY, Australia--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
and the Australia and New Zealand Melanoma Trials Group (ANZMTG) have joined forces to advance cutting edge melanoma research at the University of Sydney, it was announced today.
Read the complete article here.
June 10, 2008
Provectus Pharmaceuticals Receives US Patent Providing Further Protection for Novel Agent PH-12
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
has received its third US patent protecting novel therapeutic agents and methods from the United States Patent and Trademark Office (USPTO). The current patent covers radiosensitizer agents based on PH-12, the Company's novel analog of PV-10 and PH-10, designed to enhance effectiveness of radiation therapy.
Read the complete article here.
June 3, 2008
Provectus Pharmaceuticals Appoints Kelly M. McMasters, MD, PhD, to Board of Directors
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
has announced that Kelly M. McMasters MD, PhD, a preeminent authority on melanoma, has agreed to serve as a member of the corporate Board of Directors. Additionally, Dr. McMasters will head the scientific advisory board.
Read the complete article here.
|
